Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in SUPN — Supernus Pharmaceuticals, Inc.

CIK 1423053 MIAMI, FL
Back to SUPN Full portfolio

Position in SUPN

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$77,196,223
+$54,684,162 QoQ
Shares Held
1,493,446
+229.7% QoQ
Ownership
2.57%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in SUPN Over Time

Shares Held

Position Value (USD)

Derivatives in SUPN

reported options exposure · as of Mar 31, 2026
CallValue
$0
CallShares
0
PutValue
$1,788,474
PutShares
34,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $927,090,430 across 59 Drug Manufacturers - Specialty & Generic names. SUPN ranks #5 (8.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 UTHR
UNITED THERAPEUTICS Corp
 360,643 $213,854,086
2 INDV
Indivior Pharmaceuticals, Inc.
 3,574,044 $108,936,860
3 ELAN
Elanco Animal Health Inc
 4,387,127 $104,983,948
4 ALKS
Alkermes plc.
 2,241,584 $79,262,409
5 SUPN
Supernus Pharmaceuticals, Inc.
This page 		1,493,446 $77,196,223
6 ZTS
Zoetis Inc.
 501,011 $59,224,510
7 VTRS
Viatris Inc
 3,993,155 $53,947,523
8 KNSA
Kiniksa Pharmaceuticals International, plc
 474,750 $22,859,212

All Filings in SUPN

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $77,196,223 1,493,446
2026-03-31 $1,788,474 34,600
2025-12-31 $1,287,230 25,900
2025-12-31 $22,512,061 452,959
2025-09-30 $444,447 9,300
2025-09-30 $67,714,893 1,416,926
2025-06-30 $359,328 11,400
2025-06-30 $5,520,223 175,134
2025-03-31 $5,289,583 161,514
2025-03-31 $288,200 8,800
2025-03-31 $206,325 6,300
2024-12-31 $216,960 6,000
2024-12-31 $437,536 12,100
2024-12-31 $3,414,949 94,440
2024-09-30 $467,700 15,000
2024-09-30 $3,250,577 104,252
2024-09-30 $81,068 2,600
2024-06-30 $283,550 10,600
2024-06-30 $3,823,431 142,932
2024-06-30 $139,100 5,200
2024-03-31 $2,977,598 87,294
2024-03-31 $324,045 9,500
2024-03-31 $283,113 8,300
2023-12-31 $6,080,901 210,121
2023-12-31 $219,944 7,600
2023-12-31 $422,524 14,600
2023-09-30 $10,361,522 375,826
2023-09-30 $52,383 1,900
2023-09-30 $162,663 5,900
2023-06-30 $72,144 2,400
2023-06-30 $300,600 10,000
2023-06-30 $2,674,949 88,987
2023-03-31 $239,118 6,600
2023-03-31 $36,230 1,000
2023-03-31 $3,773,499 104,154
2022-12-31 $7,134 200
2022-12-31 $14,048,093 393,835
2022-12-31 $271,092 7,600
2022-09-30 $10,483,039 309,691
2022-06-30 $2,687,245 92,920
2022-06-30 $349,932 12,100
2022-03-31 $471,872 14,600
2022-03-31 $336,128 10,400
2022-03-31 $3,434,355 106,261
2021-12-31 $3,123,472 107,115
2021-12-31 $1,055,592 36,200
2021-12-31 $408,240 14,000
2021-09-30 $406,317 15,235
2021-09-30 $597,408 22,400
2021-09-30 $264,033 9,900

Report a Problem

Category
Description
Email (optional, for follow-up)